D'oh! It's back to the daily grind. IN VIVO Blog picked up on a few stories you may have missed over the lazy summer weekend.- Pretty soon they'll be putting it in the water. A couple pieces in the UK Guardian over the weekend about the potential fluoridization of statins in the UK. Followed up this morning, here, is the plan's downside.
- GPC Biotech continues to deal with the wake of its satraplatin review. Late Friday night the company reported the first class-action lawsuit it will face. And over the weekend Reuters reported that GPC's largest investor, SAP co-founder Dietmar Hopp, increased is stake in the company to more than 14% as its shares have slipped.
- A new use for those old pills. The AP reports on drug-disposal companies that can turn pharmaceuticals into energy.
- Finally, a big day for Avandia today ... more to come on the IN VIVO Blog.
